Advertisement
VIA-2291 is a potent small molecule drug that targets inflammation in theblood vessel wall, a primary disease process in atherosclerosis. It is beingdeveloped as a once-daily, oral drug to potentially decrease the risk of majoradverse cardiac events associated with inflammation, including heart attackand stroke.
Advertisement
The ACS principal study enrolled 191 patients, including more than 90patients in the MDCT sub-study. The study is designed to establish dose andsafety data in patients with ACS who have experienced a recent heart attack orunstable angina. The study includes measures of leukotrienes, biomarkers ofinflammation, as well as medical imaging of the coronary vessels to evaluatethe impact on plaque characteristics in a subset of patients. Patients in thestudy are treated once daily with one of three dose levels of VIA-2291 orplacebo.
In addition to the ACS and CEA studies, VIA is conducting a third Phase 2clinical trial, the FDG-PET Trial. Enrollment in this trial is ongoing andendpoints in this study include reduction in carotid plaque inflammationfollowing dosing with VIA-2291 as measured with state-of-the-art FDG-PETimaging technology, as well as assessment of standard biomarker measurementsof inflammation.
About VIA Pharmaceuticals, Inc.
VIA Pharmaceuticals, Inc. is a biotechnology company focused on thedevelopment of compounds for the treatment of cardiovascular disease. VIA isbuilding a pipeline of small-molecule drugs that target a significant unmetmedical need: reducing inflammation in the blood vessel wall, which is anunderlying cause of atherosclerosis and its complications, including heartattack and stroke. The company's lead drug candidate, VIA-2291, is in multiplePhase 2 clinical studies in patients with cardiovascular disease. For moreinformation, visit: http://www.viapharmaceuticals.com.
Forward-Looking Statements
This press release may contain "forward-looking" statements within themeaning of the Private Securities Litigation Reform Act of 1995. Thesestatements relate to future events or to VIA's future financial performanceand involve known and unknown risks, uncertainties and other factors that maycause VIA's actual results, levels of activity, performance or achievements tobe materially different from any future results, levels of activity,performance or achievements expressed or implied by these forward-lookingstatements. In some cases, you can identify forward-looking statements by theuse of words such as "may," "could," "expect," "intend," "plan," "seek,""anticipate," "believe," "estimate," "predict," "potential," "continue" or thenegative of these terms or other comparable terminology. You should not placeundue reliance on forward-looking statements since they involve known andunknown risks, uncertainties and other factors which are, in some cases,beyond VIA's control and which could materially affect actual results, levelsof activity, performance or achievements.
Factors that may cause actual results to differ materially from currentexpectations include, but are not limited to:
All forward-looking statements attributable to us or persons acting on ourbehalf are expressly qualified in their entirety by the cautionary
